Pharmaceutical Advertising Advisory Board edit
The Pharmaceutical Advertising Advisory Board (PAAB) is a Canadian not-for-profit organization based in Pickering, Ontario. Acting as a pseudo-regulatory body, PAAB offers review and pre-clearance services recognized by Health Canada to pharmaceutical companies and marketing agencies who wish to advertise directly to consumers and/or healthcare professionals.[1][2] It is financed on a fee-for-service basis.
It works collaboratively with Health Canada, with the federal agency represented as an ex-oficio member on PAAB's board of directors.
History edit
PAAB originated through a collaboration between the Pharmaceutical Manufacturing Association of Canada and the Canadian Medical Association.[3]
As of July 1977, all advertisements printed in the Canadian Medical Association Journal carried the PAAB seal of approval following an examination of their quality and accuracy.[3]
Organization edit
Governance edit
Board of directors edit
PAAB is governed by a board of 12 members, including representation from industry associations including Innovative Medicines Canada, BIOTECanada, Association of Medical Advertising Agencies, Canadian Association of Medical Publisher and Consumer Health Products Canada.[1][4][5]
- Lorenzo Biondi (Chair)
- Kristin Willemsen - Food, Health & Consumer Products of Canada (Vice-chair)
- Jim Hall - Canadian Association of Medical Publishers (Treasurer)
- Dr. Cecile Bensimon - Canadian Medical Association
- Jeff Connell - Canadian Generic Pharmaceutical Association
- Anita Hammer - BIOTECanada
- Sean McNamara - Canadian Dental Association
- Denis Morrice - Best Medicines Coalition
- Christine O'Reilly - Canadian Healthcare Communications Providers
- Tammy Quinn - Canadian Pharmacists Association
- Agni Shah - Consumers Council of Canada
- Crawford Wright - Innovative Medicines Canada
Activities edit
Advertising materials for all health products in Canada that are intended for healthcare professionals are submitted for review and pre-clearance by PAAB, who prescribes the guidelines for direct marketing to this group.[6] Educational materials and other messaging directed towards consumers on prescription drugs and the medical conditions they treat are reviewed by PAAB and Advertising Standards Canada to ensure compliance with regulatory requirements.[2] While these reviews are not mandatory, PAAB is obligated to forward all safety-related complaints to Health Canada.[7]
References edit
- ^ a b "PAAB : About". Pharmaceutical Advertising Advisory Board / Conseil Consultatif de Publicité Pharmaceutique. Archived from the original on 2018-09-24. Retrieved 2022-08-29.
- ^ a b Health Canada (2015-05-12). "Regulatory Requirements for Advertising". Government of Canada. Archived from the original on 2022-08-29. Retrieved 2022-08-29.
- ^ a b Geekie, D.A. (1977-05-07). "Pharmaceutical Advertising Advisory Board and advertising in the Journal". Canadian Medical Association Journal. 116 (9): 968. ISSN 0008-4409. PMC 1879061. PMID 20312852.
- ^ Lexchin, Joel (2018-04-12). "How Big Pharma deceives you about drug safety". The Conversation. Archived from the original on 2021-10-16. Retrieved 2022-08-30.
- ^ Kingston, Anne (2018-05-11). "A criminal investigation into opioid marketing would expose larger systemic rot". Maclean's. Archived from the original on 2022-08-30. Retrieved 2022-08-30.
- ^ Harris, Kelly (2020-03-31). "In brief: prohibited and controlled advertising in Canada". Lexology. Archived from the original on 2022-08-30. Retrieved 2022-08-30.
- ^ Dakin, Pauline (2014-12-10). "Prescription drug ad law notable for 'lack of teeth'". CBC News. Archived from the original on 2014-12-11. Retrieved 2022-08-29.